Kura Oncology (NASDAQ:KURA) Stock Rating Lowered by ValuEngine

Kura Oncology (NASDAQ:KURA) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Monday, ValuEngine reports.

A number of other equities analysts have also recently weighed in on KURA. Wedbush reissued a “positive” rating on shares of Kura Oncology in a research note on Wednesday, September 4th. Zacks Investment Research cut Kura Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, September 17th. JMP Securities reissued a “market outperform” rating and issued a $22.00 price target on shares of Kura Oncology in a research note on Thursday, September 5th. HC Wainwright reissued a “buy” rating and issued a $29.00 price target on shares of Kura Oncology in a research note on Friday, August 2nd. Finally, BidaskClub raised Kura Oncology from a “strong sell” rating to a “sell” rating in a research note on Friday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Kura Oncology currently has an average rating of “Buy” and a consensus price target of $27.10.

KURA traded up $0.51 during trading on Monday, reaching $14.97. The company had a trading volume of 153,846 shares, compared to its average volume of 264,000. The firm’s 50-day simple moving average is $15.19 and its 200 day simple moving average is $16.94. The company has a market cap of $676.41 million, a price-to-earnings ratio of -8.70 and a beta of 2.58. Kura Oncology has a 12-month low of $10.20 and a 12-month high of $21.42. The company has a debt-to-equity ratio of 0.03, a quick ratio of 23.50 and a current ratio of 23.50.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.03. On average, sell-side analysts expect that Kura Oncology will post -1.61 EPS for the current year.

Large investors have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd purchased a new position in Kura Oncology during the 2nd quarter valued at about $25,000. Meeder Asset Management Inc. grew its stake in Kura Oncology by 164.9% during the 2nd quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock valued at $38,000 after acquiring an additional 1,204 shares in the last quarter. Bank of Montreal Can grew its stake in Kura Oncology by 82,066.7% during the 2nd quarter. Bank of Montreal Can now owns 2,465 shares of the company’s stock valued at $49,000 after acquiring an additional 2,462 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Kura Oncology by 599.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after acquiring an additional 2,420 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Kura Oncology during the 2nd quarter valued at about $59,000. 85.46% of the stock is currently owned by institutional investors.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Recommended Story: What is a stock portfolio tracker?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.